Q3 FY2026 Earnings
Financial report interval: 2025.12.31 - 2026.03.31
Overview: Propanc Biopharma(PPCB) the EBIT is -6.4 M (+87.95%);the EPS is -7.09 (+97.73%).
Actual
YoY
Estimate
YoY
Vs estimate
YoY
EBIT
-0.01B87.95%
----
----
EPS
-7.089997.73%
----
----
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf